NCI-H2087 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

NCI cell lines

Organism

Human

Donor History

Lung adenocarcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: 51 hours. Dissociation reagent: Accutase. Seeding density: 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium + 10% DMSO for adequate post-thaw viability. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/NCI-H2087-Cells/305824

SKU: 305824 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

NCI-H2087 is a human non-small cell lung carcinoma (NSCLC) cell line derived from the metastatic site (specifically, a lymph node) of an adult patient with lung adenocarcinoma. This cell line is epithelial in morphology and is commonly utilized in studies investigating lung cancer pathogenesis, therapeutic responses, and molecular profiling of metastatic adenocarcinomas. It exhibits characteristics consistent with its origin, including expression of epithelial markers and various genetic alterations typical of lung adenocarcinomas. Genetically, NCI-H2087 is known to harbor mutations relevant to oncogenesis and therapy resistance in NSCLC. Most notably, it contains a KRAS mutation, which is associated with constitutive activation of downstream signaling pathways such as MAPK and PI3K-AKT, leading to enhanced cell proliferation and survival. The presence of this mutation makes NCI-H2087 a valuable model for studying KRAS-driven tumorigenesis and for evaluating targeted inhibitors that disrupt KRAS signaling. Additionally, the cell line is p53 mutant, which can contribute to impaired apoptosis and genomic instability, further supporting its utility in preclinical cancer biology and drug screening research.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.